Drug Search Results
More Filters [+]

Furazolidone

Alternative Names: furazolidone, furoxone, furazolidona
Latest Update: 2024-08-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: MAO Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Brazil | Chile | China | Colombia | Dominican Republic | Ecuador | India | Indonesia | Ireland | Italy | New Zealand | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Taiwan | Turkey | Ukraine | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Furazolidone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Helicobacter Infections|Communicable Diseases|Gastrointestinal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ChiCTR2400087082

N/A

Not yet recruiting

Helicobacter Infections

2026-06-30

ChiCTR2300073347

N/A

Not yet recruiting

Helicobacter Infections

2024-12-31

KY20240123-05

N/A

Not yet recruiting

Helicobacter Infections

2024-12-31

NCT05718609

P4

Recruiting

Communicable Diseases|Helicobacter Infections

2024-03-01

Recent News Events

Date

Type

Title